Open access
Sep 2026
Cabozantinib After Immunotherapy in Advanced Renal Cell Carcinoma. The CARE Study by the Hellenic Gu Cancer Group
Background The widespread use of immune checkpoint inhibitor (ICI)–based combinations as first-line therapy for metastatic renal cell carcinoma (mRCC) has created an unmet need for effective treatment options at disease progression. Cabozantinib is recommended after ICI failure; however, real-world evidence regarding i...
A. Bamias, Michael Liontos, I. Binas et al.
· Cancer Management and Resear... · 0 citations